Biggest changeCash Flows Summary The net change in cash and cash equivalents and restricted cash for the periods presented was comprised of the following: Years Ended December 31, 2023 2022 (In thousands) Net cash provided by (used in): Operating activities $ (22,506) $ (37,336) Investing activities 16,178 184,464 Financing activities 58,632 (166,137) Effect of exchange rates on cash and cash equivalents 1 (2,566) Increase (decrease) in cash and cash equivalents $ 52,305 $ (21,575) 47 Table of Contents Cash Flows from Operating Activities Cash flows from operating activities were comprised of the following for the periods presented: Years Ended December 31, 2023 2022 (In thousands) Net income (loss) including noncontrolling interests in subsidiaries $ 68,930 $ (110,939) Adjustments to reconcile net income (loss) including noncontrolling interests in subsidiaries to net cash used in operating activities: Depreciation, depletion and amortization 14,728 13,514 Amortization of debt discount and issuance costs — 90 Change in fair values Series A redeemable convertible preferred stock embedded derivatives, Series A warrants and Series B warrants (6,716) (15,106) Loss on exercise of Series A warrants — 2,004 Gain on exercise of Series B warrants (1,525) — Compensation expense for share-based awards 3,297 3,820 (Gain) loss on foreign currency exchange (53) 3,324 Change in fair value of equity securities (31,423) 263,695 Loss (gain) on sale of equity securities 10,930 (125,318) Unrealized gain on derivatives (781) — Earnings on equity investment in joint venture (4,167) (42,531) Deferred income taxes (3,657) (17,810) Changes in assets and liabilities: Accounts receivable (70,313) 998 Inventories 3,301 (5,291) Prepaid expenses and other assets (820) (5,986) Accounts payable and accrued expenses (4,651) (136) Royalties and contingent legal fees payable 751 (1,764) Deferred revenue (337) 100 Net cash used in operating activities $ (22,506) $ (37,336) Cash receipts from ARG's licensees totaled $12.2 million and $16.6 million for the years ended December 31, 2023 and 2022, respectively.
Biggest changeRefer to Note 11 to the accompanying consolidated financial statements for additional information. 71 Table of Contents Cash Flows Summary The net change in cash and cash equivalents for the periods presented was comprised of the following: Years Ended December 31, 2024 2023 (In thousands) Net cash (used in) provided by: Operating activities $ 50,122 $ (22,506) Investing activities (212,963) 16,178 Financing activities 97,556 58,632 Effect of exchange rates on cash and cash equivalents (926) 1 (Decrease) increase in cash and cash equivalents $ (66,211) $ 52,305 Cash Flows from Operating Activities Cash flows from operating activities were comprised of the following for the periods presented: Years Ended December 31, 2024 2023 (In thousands) Net (loss) income including noncontrolling interests in subsidiaries $ (34,698) $ 68,930 Adjustments to reconcile net loss including noncontrolling interests in subsidiaries to net cash provided by (used in) operating activities: Depreciation, depletion and amortization 33,574 14,728 Accretion of asset retirement obligation 986 — Change in fair values Series A redeemable convertible preferred stock embedded derivatives and Series B warrants — (6,716) Gain on exercise of Series B warrants — (1,525) Compensation expense for share-based awards 4,795 3,297 Loss (gain) on foreign currency exchange 370 (53) Change in fair value of equity securities 31,412 (31,423) (Gain) loss on sale of equity securities (28,861) 10,930 Unrealized loss (gain) on derivatives 610 (781) Earnings on equity investment in joint venture — (4,167) Deferred income taxes, net of acquired net deferred tax assets (6,051) (3,657) Changes in assets and liabilities: Accounts receivable 69,225 (70,313) Inventories 1,054 3,301 Prepaid expenses and other assets (9,329) (820) Accounts payable and accrued expenses (8,124) (4,651) Royalties and contingent legal fees payable (5,338) 751 Deferred revenue 497 (337) Net cash provided by (used in) operating activities $ 50,122 $ (22,506) 72 Table of Contents Cash receipts from ARG’s licensees totaled $91.3 million and $12.2 million for the years ended December 31, 2024 and 2023, respectively.
We are particularly attracted to complex situations where we believe value is not fully recognized, the value of certain operations are masked by a diversified business mix, or where private ownership has not invested the capital and/or resources necessary to support long-term value.
We are particularly attracted to complex situations where we believe value is not fully recognized, the value of certain operations is masked by a diversified business mix, or where private ownership has not invested the capital and/or resources necessary to support long-term value.
Acacia has made a control investment in Benchmark and intends to utilize its significant capital base to acquire predictable and shallow decline, cash-flowing oil and gas properties whose value can be enhanced via a disciplined, field optimization strategy, with risk managed through robust commodity hedges and low leverage.
Acacia made a control investment in Benchmark and intends to utilize its significant capital base to acquire predictable and shallow decline, cash-flowing oil and gas properties whose value can be enhanced via a disciplined, field optimization strategy, with risk managed through robust commodity hedges and low leverage.
We believe this business model is differentiated from private equity funds, which do not typically own public securities prior to acquiring companies, hedge funds, which do not typically acquire entire businesses, and other acquisition vehicles such Special Purpose Acquisition Companies, which are narrowly focused on completing one singular, defining acquisition.
We believe this business model is differentiated from private equity funds, which do not typically own public securities prior to acquiring companies, hedge funds, which do not typically acquire entire businesses, and other acquisition vehicles such as special purpose acquisition companies, which are narrowly focused on completing one singular, defining acquisition.
We focus on identifying, pursuing and acquiring businesses where we are uniquely positioned to deploy our differentiated strategy, people and processes to generate and compound shareholder value. We have a wide range of transactional and operational capabilities to realize the intrinsic value in the businesses that we acquire.
We focus on identifying, pursuing and acquiring businesses where we are uniquely positioned to deploy our differentiated strategy, people and processes to generate and compound shareholder value. We have a wide range of transactional and operational capabilities to realize the intrinsic value of the businesses that we acquire.
For additional information regarding ARG's patent portfolio valuation estimates, refer to Note 2 to the consolidated financial statements. The Company did not record any long-lived asset, patent or other intangible asset impairment charges for the years ended December 31, 2023 and 2022. Goodwill asset impairment reviews include determining the estimated fair values of our reporting units.
For additional information regarding ARG’s patent portfolio valuation estimates, refer to Note 2 to the consolidated financial statements. The Company did not record any long-lived asset, patent or other intangible asset impairment charges for the years ended December 31, 2024 and 2023. Goodwill asset impairment reviews include determining the estimated fair values of our reporting units.
Due to uncertainties related to our ability to utilize certain deferred tax assets in future periods, we have recorded a partial valuation allowance against our net deferred tax assets as of December 31, 2023 and 2022. These assets primarily consist of foreign tax credits and net operating loss carryforwards.
Due to uncertainties related to our ability to utilize certain deferred tax assets in future periods, we have recorded a partial valuation allowance against our net deferred tax assets as of December 31, 2024 and 2023. These assets primarily consist of foreign tax credits and net operating loss carryforwards.
We may, however, encounter unforeseen difficulties that may deplete our capital resources more rapidly than anticipated, including those set forth under Item 1A, “Risk Factors”. Any efforts to seek additional funding could be made through issuances of equity or debt, or other external financing. However, additional funding may not be available to us on favorable terms, or at all.
We may, however, encounter unforeseen difficulties that may deplete our capital resources more rapidly than anticipated, including those set forth under Item 1A, “Risk Factors.” Any efforts to seek additional funding could be made through issuances of equity or debt, or other external financing. However, additional funding may not be available to us on favorable terms, or at all.
The decrease in Printronix's cost of revenues for the year ended December 31, 2023 is due to change in revenue described above. Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding Printronix's cost of sales.
The decrease in Printronix's cost of revenues for the year ended December 31, 2024 is due to change in revenue described above. Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding Printronix’s cost of sales.
Through its investment in Benchmark, the Company, along with the Benchmark management team, will evaluate future growth and acquisitions of oil and gas assets at attractive valuations. The Company’s consolidated financial statements include Benchmark’s consolidated operations from November 13, 2023 through December 31, 2023. Refer to Note 3 to the consolidated financial statements elsewhere herein for additional information.
Through its investment in Benchmark, the Company, along with the Benchmark management team, will evaluate future growth and acquisitions of oil and gas assets at attractive valuations. The Company’s consolidated financial statements include Benchmark’s consolidated operations from November 13, 2023 through December 31, 2024. Refer to Note 1 to the consolidated financial statements elsewhere herein for additional information.
Patent Licensing and Enforcement Patent Litigation Trial Dates and Related Trials As of the date of this Annual Report, our Patent Licensing, Enforcement and Technologies Business has one pending patent infringement case with scheduled trial dates in the next twelve months.
Patent Licensing and Enforcement Patent Litigation Trial Dates and Related Trials As of the date of this Annual Report, our Patent Licensing, Enforcement and Technologies Business has two pending patent infringement case with scheduled trial dates in the next twelve months.
We believe our priorities and skills underpin a compelling value proposition for operating businesses, partners and future acquisition targets, including: • the flexibility to consummate transactions using financing structures suited to the opportunity and involving third-party transaction structuring as needed; 34 Table of Contents • the ability to deliver ongoing financial and strategic support; and • the financial capacity to maintain a long-term outlook and remain committed to a multi-year business plan.
We believe our priorities and skills underpin a compelling value proposition for operating businesses, partners and future acquisition targets, including: • the flexibility to consummate transactions using financing structures suited to the opportunity and involving third-party transaction structuring as needed; • the ability to deliver ongoing financial and strategic support; and • the financial capacity to maintain a long-term outlook and remain committed to a multi-year business plan.
Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding our revenue arrangements and related concentrations for the periods presented herein. Refer to “Investments in Patent Portfolios” above for information regarding the impact of portfolio acquisition trends on current and future licensing and enforcement related revenues.
Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding our revenue arrangements and related concentrations for the periods presented herein. 65 Table of Contents Refer to “Investments in Patent Portfolios” above for information regarding the impact of portfolio acquisition trends on current and future licensing and enforcement related revenues.
To the extent we establish a valuation allowance or increase this allowance in a period, we must include an expense within the tax provision in the consolidated statements of operations. 51 Table of Contents Significant management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and our valuation allowance.
To the extent we establish a valuation allowance or increase this allowance in a period, we must include an expense within the tax provision in the consolidated statements of operations. Significant management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and our valuation allowance.
Unlike most operating businesses and industries, licensing revenues not generated in a current period are not necessarily foregone but, depending on whether negotiations, litigation or both continue into subsequent periods, and depending on a number of other factors, such potential revenues may be pushed into subsequent annual periods.
Unlike most operating businesses and industries, licensing revenues not generated in a current period are not necessarily foregone but, depending on whether negotiations, litigation or both continue into subsequent periods, and depending on several other factors, such potential revenues may be pushed into subsequent annual periods.
The patents and patent rights acquired in 2021 and 2020 have estimated economic useful lives of approximately five years. Industrial Operations Business 38 Table of Contents Our Printronix subsidiary is a worldwide leader in multi‐technology supply‐chain printing solutions for a variety of industries, including manufacturing, transportation and logistics, retail distribution, food and beverage distribution, and pharmaceutical distribution.
The patents and patent rights acquired in 2021 and 2020 have estimated economic useful lives of approximately five years. Industrial Operations Business Our Printronix subsidiary is a worldwide leader in multi‐technology supply‐chain printing solutions for a variety of industries, including auto manufacturing, transportation and logistics, retail distribution, food and beverage distribution, and pharmaceutical distribution.
In preparing these financial statements, we make assumptions, judgments and estimates that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our 49 Table of Contents financial condition or results of operations.
In preparing these financial statements, we make assumptions, judgments and estimates that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations.
Our management believes that our cash and cash equivalent balances and cash flows from operations will be sufficient to meet our cash requirements through at least twelve months from the date of this Annual Report and for the foreseeable 46 Table of Contents future.
Our management believes that our cash and cash equivalent balances and cash flows from operations will be sufficient to meet our cash requirements through at least twelve months from the date of this Annual Report and for the foreseeable future.
In such event, a court may issue monetary sanctions against us or our operating subsidiaries or award attorney’s fees and/or expenses to a defendant(s), which could be material. At December 31, 2023, our primary sources of liquidity are cash and cash equivalents on hand and cash generated from our operating activities.
In such event, a court may issue monetary sanctions against us or our operating subsidiaries or award attorney’s fees and/or expenses to a defendant(s), which could be material. At December 31, 2024, our primary sources of liquidity were cash and cash equivalents on hand and cash generated from our operating activities.
Our actual results could differ materially from those anticipated in these “forward-looking statements” as a result of various factors including the risks we discuss in Item 1A “Risk Factors,” and elsewhere herein.
Our actual results could differ materially from those anticipated in these “forward-looking statements” as a result of various factors including the risks we discuss in Item 1A. "Risk Factors," and elsewhere herein.
In the event the expected undiscounted future cash flows resulting from the use of the asset is less than the carrying amount of the asset, an impairment loss is recorded in an amount equal to the excess of the asset’s carrying value over its fair value.
In the event the expected undiscounted future cash flows resulting from the use of the asset is less than the carrying amount of 75 Table of Contents the asset, an impairment loss is recorded in an amount equal to the excess of the asset’s carrying value over its fair value.
We discuss below the critical accounting assumptions, judgements and estimates associated with these policies. Historically, our critical accounting estimates relative to our significant accounting policies have not differed materially from actual results. For further information on the related significant accounting policies, refer to Note 2 to the consolidated financial statements.
We discuss below the critical accounting assumptions, judgements and estimates associated with these policies. Historically, our critical accounting estimates relative to our significant accounting policies have not differed materially 74 Table of Contents from actual results. For further information on the related significant accounting policies, refer to Note 2 to the consolidated financial statements.
The oil and natural gas industry and the broader U.S. economy have 37 Table of Contents experienced higher than expected inflationary pressures in recent years related to increases in oil and natural gas prices, continued supply chain disruptions, labor shortages and geopolitical instability, among other pressures.
The oil and natural gas industry and the broader U.S. economy have experienced higher than expected inflationary pressures in recent years related to increases in oil and natural gas prices, continued supply chain disruptions, labor shortages and geopolitical instability, among other pressures.
Estimated crude oil and natural gas reserves affect the 50 Table of Contents carrying value of oil and gas properties, depreciation, depletion and amortizations, asset retirement obligations, and evaluation of impairment of oil and natural gas properties. Changes in the estimated reserves could have a significant impact on future results of operations.
Estimated crude oil, natural gas and NGL reserves affect the carrying value of oil and gas properties, depreciation, depletion and amortizations, asset retirement obligations, and evaluation of impairment of oil and natural gas properties. Changes in the estimated reserves could have a significant impact on future results of operations.
If we fail to obtain additional financing when needed, we may not be able to execute our business plans and our business, conducted by our operating subsidiaries, may suffer. Cash, Cash Equivalents and Investments Our consolidated cash, cash equivalents and equity securities totaled $403.2 million at December 31, 2023, compared to $349.4 million at December 31, 2022.
If we fail to obtain additional financing when needed, we may not be able to execute our business plans and our business, conducted by our operating subsidiaries, may suffer. Cash, Cash Equivalents and Investments Our consolidated cash, cash equivalents and equity securities totaled $297.0 million at December 31, 2024, compared to $403.2 million at December 31, 2023.
In addition to the following results of operations discussion, more information related to our Intellectual Property Operations, Industrial Operations and Energy Operations segment revenues, cost of revenues and cost of production may be found in Notes 2 and 19 to the consolidated financial statements.
In addition to the following results of operations discussion, more information related to our Intellectual Property Operations, Industrial Operations, Energy Operations and Manufacturing Operations segment revenues may be found in Notes 2 and 21 to the consolidated financial statements.
Patent Portfolio Intake One of the significant challenges in the intellectual property industry continues to be quality patent intake due to the challenges and complexity associated with the current patent environment. During the years ended December 31, 2023 and 2022, we did not acquire any new patent portfolios.
Patent Portfolio Intake One of the significant challenges in the intellectual property industry continues to be quality patent intake due to the challenges and complexity associated with the current patent environment. We did not acquire any new patent portfolios in calendar years 2024 , 2023 and 2022 .
Energy Operations In November 2023, we invested $10.0 million to acquire a 50.4% equity interest in Benchmark. Headquartered in Austin, Texas, Benchmark is an independent oil and gas company engaged in the acquisition, production and development of oil 35 Table of Contents and gas assets in mature resource plays in Texas and Oklahoma.
Recent Acquisitions In November 2023, we invested $10.0 million to acquire a 50.4% equity interest in Benchmark. Headquartered in Austin, Texas, Benchmark is an independent oil and gas company engaged in the acquisition, production and development of oil and gas assets in mature resource plays in Texas and Oklahoma.
During the fourth quarter of 2022, Acacia fully exited its position in Oxford Nanopore. Refer to periodic change explanations above. Refer to Notes 2 and 4 to the consolidated financial statements elsewhere herein for additional information regarding our investment in the Life Sciences Portfolio and other equity securities.
During the first quarter of 2024, Acacia fully exited its position in Arix. Refer to periodic change explanations above. Refer to Notes 2 and 4 to the consolidated financial statements elsewhere herein for additional information regarding our investment in the Life Sciences Portfolio and other equity securities.
Working Capital Our working capital related to cash flows from operating activities at December 31, 2023 increased to $87.0 million, compared to $15.1 million at December 31, 2022, which was comprised of the changes in assets and liabilities presented above.
Working Capital Our working capital related to cash flows from operating activities at December 31, 2024 decreased to $39.1 million, compared to $87.0 million at December 31, 2023, which was comprised of the changes in assets and liabilities presented above.
Refer to Note 17 to the consolidated financial statements for additional information.
Refer to Note 19 to the consolidated financial statements for additional information.
Liquidity and Capital Resources General Our foreseeable material cash requirements as of December 31, 2023, are recognized as liabilities or generally are otherwise described in Note 13, "Commitments and Contingencies," to the consolidated financial statements included elsewhere herein.
Liquidity and Capital Resources General Our foreseeable material cash requirements as of December 31, 2024, are recognized as liabilities or generally are otherwise described in Note 15, “Commitments and Contingencies,” to the consolidated financial statements included elsewhere herein.
For more information related to our Intellectual Property Operations, refer to additional detailed patent business discussion below. Industrial Operations In October 2021, we consummated our first operating company acquisition of Printronix. Printronix is a leading manufacturer and distributor of industrial impact printers, also known as line matrix printers, and related consumables and services.
For more information related to our Intellectual Property Operations, refer to additional detailed patent business discussion below. Industrial Operations In October 2021, we acquired Printronix Holding Corp. (“Printronix”). Printronix is a leading manufacturer and distributor of industrial impact printers, also known as line matrix printers, and related consumables and services.
Operating Activities Intellectual Property Operations Our Intellectual Property Operations revenues historically have fluctuated quarterly, and can vary significantly period to period, based on a number of factors including the following: • the dollar amount of agreements executed each period, which can be driven by the nature and characteristics of the technology or technologies being licensed and the magnitude of infringement associated with a specific licensee; • the specific terms and conditions of agreements executed each period including the nature and characteristics of rights granted, and the periods of infringement or term of use contemplated by the respective payments; • fluctuations in the total number of agreements executed each period; • the number of, timing, results and uncertainties associated with patent licensing negotiations, mediations, patent infringement actions, trial dates and other enforcement proceedings relating to our patent licensing and enforcement programs; • the relative maturity of licensing programs during the applicable periods; • other external factors, including the periodic status or results of ongoing negotiations, the status or results of ongoing litigations and appeals, actual or perceived shifts in the regulatory environment, impact of unrelated patent related judicial proceedings and other macroeconomic factors; • the willingness of prospective licensees to settle significant patent infringement cases and pay reasonable license fees for the use of our patented technology, as such infringement cases approached a court determined trial date; and • fluctuations in overall patent portfolio related enforcement activities which are impacted by the portfolio intake challenges discussed above. 39 Table of Contents Our management does not attempt to manage for smooth sequential periodic growth in revenues from period to period, and therefore, periodic results can be uneven.
Deflecto manufactures its products at nine manufacturing facilities across the United States, Canada, the United Kingdom and China Operating Activities Intellectual Property Operations Our Intellectual Property Operations revenues historically have fluctuated quarterly, and can vary significantly period to period, based on several factors including the following: • the dollar amount of agreements executed each period, which can be driven by the nature and characteristics of the technology or technologies being licensed and the magnitude of infringement associated with a specific licensee; • the specific terms and conditions of agreements executed each period including the nature and characteristics of rights granted, and the periods of infringement or term of use contemplated by the respective payments; • fluctuations in the total number of agreements executed each period; • the number of, timing, results and uncertainties associated with patent licensing negotiations, mediations, patent infringement actions, trial dates and other enforcement proceedings relating to our patent licensing and enforcement programs; • the relative maturity of licensing programs during the applicable periods; • other external factors, including the periodic status or results of ongoing negotiations, the status or results of ongoing litigations and appeals, actual or perceived shifts in the regulatory environment, impact of unrelated patent related judicial proceedings and other macroeconomic factors; • the willingness of prospective licensees to settle significant patent infringement cases and pay reasonable license fees for the use of our patented technology, as such infringement cases approach a court determined trial date; and • fluctuations in overall patent portfolio related enforcement activities which are impacted by the portfolio intake challenges discussed above.
We believe that of the significant accounting policies discussed in Note 2 to the consolidated financial statements included elsewhere herein, the following accounting policies require our most difficult, subjective or complex assumptions, judgments and estimates: • revenue recognition; • estimates of crude oil and natural gas reserves • valuation of long-lived assets, goodwill and other intangible assets; • valuation of Series B Warrants; • valuation of embedded derivatives; and • accounting for income taxes.
We believe that of the significant accounting policies discussed in Note 2 to the consolidated financial statements included elsewhere herein, the following accounting policies require our most difficult, subjective or complex assumptions, judgments and estimates: • revenue recognition; • estimates of crude oil and natural gas reserves and values and standardized measure of discounted future net cash flows • valuation of long-lived assets, goodwill and other intangible assets; • accounting for income taxes.
The current period unrealized gain primarily relates to our Life Sciences Portfolio and trading securities portfolio. The current period realized loss primarily relates to sales activity from trading securities portfolio. During 2023, we recorded consolidated earnings on equity investment in joint venture, which is part of the Life Sciences Portfolio, of $4.2 million for two milestones earned during the period.
These changes were derived from our Life Sciences Portfolio and trading securities portfolio. The 2024 period unrealized loss and realized gain primarily relates to the sale of Arix shares. During 2023, we recorded consolidated earnings on equity investment in joint venture, which is part of the Life Sciences Portfolio, of $4.2 million for two milestones earned during the period.
The increase in variable performance-based compensation costs was primarily due to fluctuations in performance-based compensation accruals. The decrease in other general and administrative costs, which relates to our parent company and Intellectual Property Operations business, were primarily due to lower legal fees.
The increase in variable performance-based compensation costs was primarily due to fluctuations in performance-based compensation. The increase in other general and administrative costs, which relates to our parent company and our Intellectual Property Operations, were primarily due to increases in accounting professional fees.
The unrealized gain and loss were derived from our Life Sciences Portfolio and trading securities portfolio. The prior year unrealized loss primarily relates to the reversal of unrealized gains previously recorded for shares sold during the year for realized gains.
The unrealized gain and loss were derived from our Life Sciences Portfolio and trading securities portfolio. The 2024 period unrealized loss primarily relates to the reversal of unrealized gains previously recorded for Arix shares sold in January 2024 for realized gains.
Intellectual Property Operations The Company through its Patent Licensing, Enforcement and Technologies Business invests in IP and related absolute return assets and engage in the licensing and enforcement of patented technologies.
Intellectual Property Operations The Company through its Patent Licensing, Enforcement and Technologies Business invests in IP and engages in the licensing and enforcement of patented technologies.
The Company has recorded a partial valuation allowance against our net deferred tax assets as of December 31, 2023 and 2022. Refer to Notes 2 and 17 to the consolidated financial statements elsewhere herein for additional income tax information.
The Company has recorded a partial valuation allowance against our net deferred tax assets as of December 31, 2024 and 2023 on foreign tax credits and certain state net operating losses. Refer to Notes 2 and 19 to the consolidated financial statements elsewhere herein for additional income tax information.
Estimate of Crude Oil and Natural Gas Reserves Estimates of crude oil and natural gas reserves, as determined by independent petroleum engineers, are continually subject to revision based on price, production history and other factors.
Estimate of Crude Oil and Natural Gas Reserves and Values and Standardized Measure of Discounted Future Net Cash Flows Estimates of crude oil, natural gas and NGL reserves, as determined by independent petroleum engineers, are continually subject to revision based on price, production history and other factors.
Intellectual Property Operations Revenues ARG's revenue activity for the periods presented included the following: Years Ended December 31, 2023 2022 $ Change % Change (In thousands, except percentage change values and count totals) Paid-up license revenue agreements $ 87,835 $ 17,788 $ 70,047 394 % Recurring license revenue agreements 1,321 1,720 (399) (23 %) Total revenues $ 89,156 $ 19,508 $ 69,648 357 % New license agreements executed 16 17 (1) (6 %) Licensing and enforcement programs generating revenues 7 8 (1) (13 %) For the periods presented above, the majority of the revenue agreements executed during the relevant period provided for the payment of one-time, paid-up license fees in consideration for the grant of certain IP Rights for patented technology owned by our operating subsidiaries.
Intellectual Property Operations Revenues ARG’s revenue activity for the periods presented included the following: Years Ended December 31, 2024 2023 $ Change % Change (In thousands, except percentage change values and count totals) Paid-up license revenue agreements $ 17,253 $ 87,835 $ (70,582) (80 %) Recurring license revenue agreements 2,272 1,321 951 72 % Total revenues $ 19,525 $ 89,156 $ (69,631) (78 %) New license agreements executed 9 16 (7) (44 %) Licensing and enforcement programs generating revenues 6 7 (1) (14 %) For the periods presented above, the majority of the revenue agreements executed during the relevant period provided for the payment of one-time, paid-up license fees in consideration for the grant of certain IP Rights for patented technology owned by our operating subsidiaries.
Results of Operations The results reflected in this section with respect to Benchmark for the year ended December 31, 2023 include results for the period from November 13, 2023 to December 31, 2023 following our acquisition of Benchmark.
Results of Operations The results reflected in this section with respect to Deflecto for the year ended December 31, 2024 include results for the period from October 18, 2024 to December 31, 2024 following our acquisition of Deflecto.
As of December 31, 2023, we have generated gross licensing revenue of approximately $1.8 billion, and have returned $865.2 million to our patent partners. During the past five calendar years ending on December 31, 2023, we generated gross licensing revenue of approximately $225.7 million and returned approximately $84.9 million to our patent partners.
As of December 31, 2024, we have generated gross licensing revenue of approximately $1.9 billion, and have returned $881.0 million to our patent partners. During the past five calendar years ending on December 31, 2024, we generated gross licensing revenue of approximately $234.0 million and returned approximately $91.2 million to our patent partners.
This acquisition was made at what we believe to be an attractive purchase price, and we are now supporting existing management in its initiative to reduce costs and operate more efficiently and in its execution of strategic partnerships to generate growth. For more information related to our Industrial Operations, refer to the section entitled “ Industrial Operations Business ” below.
This acquisition was made at what we believe to be an attractive purchase price, and we are now supporting existing management in its initiative to reduce costs and operate more efficiently and in its execution of strategic partnerships to generate growth.
Our results included an unrealized gain from the change in fair value of our equity securities as compared to an unrealized loss in the prior year, and included realized loss from the sale of our equity securities as compared to a realized gain in the prior year. These changes were derived from our Life Sciences Portfolio and trading securities portfolio.
Our results included an unrealized loss from the change in fair value of our equity securities as compared to an unrealized gain in the comparable prior period, and included realized gain from the sale of our equity securities as compared to a realized loss in the prior year.
Cash receipts from Printronix's customers totaled $37.3 million and $40.5 million for the years ended December 31, 2023 and 2022, respectively. Cash receipts from Benchmark's customers totaled $1.8 million for the post acquisition period from November 13, 2023 through December 31, 2023.
Cash receipts from Printronix's customers totaled $31.0 million and $37.3 million for the years ended December 31, 2024 and 2023, respectively. Cash receipts from Benchmark’s customers totaled $61.7 million for the year ended December 31, 2024 and $1.8 million for the period from November 13, 2023 through December 31, 2023.
These differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheets. We must then assess the likelihood that our deferred tax assets will be recovered from future taxable income and to the extent we believe that recovery is not likely, we must establish a valuation allowance.
We must then assess the likelihood that our deferred tax assets will be recovered from future taxable income and to the extent we believe that recovery is not likely, we must establish a valuation allowance.
Cash requirements are generally derived from our operating and investing activities including expenditures for working capital (discussed below), human capital, business development, investments in equity securities and intellectual property, and business combinations. Our facilities lease obligations, guarantees and certain contingent obligations are further described in Note 13 to the consolidated financial statements.
The obligations of our Energy Operations Business related to the asset retirement obligations are further described in Note 10 to the accompanying consolidated financial statements. Additional cash requirements are generally derived from our operating and investing activities including expenditures for working capital (discussed below), human capital, business development, investments in equity securities and intellectual property, and business combinations.
Investments in Patent Portfolios With respect to our licensing, enforcement and overall business, neither we nor our operating subsidiaries invent new technologies or products; rather, we depend upon the identification and investment in patents, inventions and companies that own IP through our relationships with inventors, universities, research institutions, technology companies and others.
Refer to Item 1A “Risk Factors” of this Annual Report for additional information regarding litigation and licensing expense risk. 60 Table of Contents Investments in Patent Portfolios With respect to our licensing, enforcement and overall business, neither we nor our operating subsidiaries invent new technologies or products; rather, we depend upon the identification and investment in patents, inventions and companies that own IP through our relationships with inventors, universities, research institutions, technology companies and others.
Through its investment in Benchmark, the Company, along with the Benchmark management team, will evaluate future growth and acquisitions of oil and gas assets at attractive valuations.
Through its investment in Benchmark, the Company, along with the Benchmark management team, will evaluate future growth and acquisitions of oil and gas assets at attractive valuations. 61 Table of Contents Manufacturing Operations Business In October 2024, we acquired Deflecto.
Refer to "Intellectual Property Operations – Cost of Revenues " below for further discussion. 40 Table of Contents • Contingent legal fees increased $8.6 million, from $2.4 million to $11.0 million in 2023, primarily due to the change in Intellectual Property Operations revenues described above.
Refer to “Intellectual Property Operations – Cost of Revenues” below for further discussion. • Contingent legal fees decreased $8.7 million, from $11.0 million to $2.3 million in 2024, primarily due to the change in Intellectual Property Operations revenues described above.
The decrease in cash used in operations was primarily due to net outflows from the total changes in assets and liabilities (refer to Working Capital discussion below), increase in accounts receivable and inventory related sales, and by the total change in net income (described above) and related noncash adjustments.
The increase in cash provided by operations was primarily due to net inflows from the total changes in assets and liabilities (refer to Working Capital discussion below), decrease in accounts receivable, decrease in inventories, increase in prepaid expense and other assets, decrease in accounts payable, decrease in royalties and contingent legal fees payable and by the total change in net income (described above) and related noncash adjustments.
Any changes in the judgments, assumptions and estimates associated with our analysis of the need for a valuation allowance in any future periods could materially impact our financial position and results of operations in the periods in which those determinations are made. Recent Accounting Pronouncements Refer to Note 2 to consolidated financial statements included elsewhere herein. 52 Table of Contents
Any changes in the judgments, assumptions and estimates associated with our analysis of the need for a valuation allowance in any future periods could materially impact our financial position and results of operations in the periods in which those determinations are made.
Relationship with Starboard Value, LP Our strategic relationship with Starboard provides us access to industry expertise, and operating partners and industry experts to evaluate potential acquisition opportunities and enhance the oversight and value creation of such businesses once acquired.
Relationship with Starboard Value, LP Our strategic relationship with Starboard enhances our access to operating partners and industry experts with whom we evaluate potential acquisition opportunities, which enhances the oversight and value creation of our businesses.
ARG revenues increased due to one patent portfolio that generated license revenue in the fourth quarter of 2023, which contributed to Intellectual Property Operations revenues increasing by $69.6 million. Refer to “Investments in Patent Portfolios” above for additional information regarding the impact of portfolio acquisition trends on current and future licensing and enforcement related revenues.
ARG revenues decreased due to a decrease in the number of license agreements executed and a decrease in average license fees, which contributed to Intellectual Property Operations revenues decreasing by $69.6 million. Refer to “Investments in Patent Portfolios” above for additional information regarding the impact of portfolio acquisition trends on current and future licensing and enforcement related revenues.
The Company's goodwill balance relates to primarily Printronix, which was acquired on October 7, 2021, and Benchmark, which was acquired on November 13, 2023, refer to Notes 1 and 3 to the consolidated financial statements for additional information. The Company did not record any goodwill impairment charges for the years ended December 31, 2023 and 2022.
The Company’s goodwill balance relates to primarily Printronix, which was acquired on October 7, 2021, Benchmark, which was acquired on November 13, 2023, and Deflecto, which was acquired on October 18, 2024, refer to Notes 1 and 3 to the consolidated financial statements for additional information.
Refer to Note 2 to the consolidated financial statements elsewhere herein for the additional information regarding the limited unsecured notes. The decrease in general and administrative costs of Industrial Operations is due to Printronix's initiative to reduce costs and operate more efficiently. Non-recurring employee severance costs fluctuate based on the severance arrangements of terminated employees.
The decrease in general and administrative costs of Industrial Operations is due to Printronix’s initiative to reduce costs and operate more efficiently. Non-recurring employee severance costs fluctuate based on the severance arrangements of terminated employees.
Industrial Operations Revenues Printronix's net revenues for the periods presented included the following: Years Ended December 31, 2023 2022 $ Change % Change (In thousands, except percentage change value) Printers and parts $ 12,513 $ 16,118 $ (3,605) (22 %) Consumable products 19,091 19,314 (223) (1 %) Services 3,494 4,283 (789) (18 %) Total $ 35,098 $ 39,715 $ (4,617) (12 %) For the periods presented above, the majority of the contract agreements executed in the relevant period include various combinations of tangible products (which include printers, consumables and parts) and services.
Industrial Operations Revenues Printronix's net revenues for the periods presented included the following: Years Ended December 31, 2024 2023 $ Change % Change (In thousands, except percentage change value) Printers and parts $ 10,021 $ 12,513 $ (2,492) (20 %) Consumable products 17,054 19,091 (2,037) (11 %) Services 3,346 3,494 (148) (4 %) Total $ 30,421 $ 35,098 $ (4,677) (13 %) For the periods presented above, the majority of the contract agreements executed in the relevant period include various combinations of tangible products (which include printers, consumables and parts) and services.
We consider opportunities based on the attractiveness of the underlying cash flows, without regard to a specific fund life or investment horizon. People, Process and Performance Our Company is built on the principles of People, Process and Performance. We have built a management team with demonstrated expertise in Research, Transactions and Execution, and Operations and Management of our targeted acquisitions.
People, Process and Performance Our Company is built on the principles of People, Process and Performance. We have built a management team with demonstrated expertise in Research, Transactions and Execution, and Operations and Management of our targeted acquisitions.
General and Administrative Expenses A summary of the main drivers of the change in general and administrative expenses is as follows: Years Ended December 31, 2023 vs. 2022 (In thousands) Personnel costs and board fees $ (1,005) Variable performance-based compensation costs 1,047 Other general and administrative costs (3,772) General and administrative costs - industrial operations (1,264) General and administrative costs - energy operations 264 Compensation expense for share-based awards (523) Non-recurring employee severance costs (3,733) Total change in general and administrative expenses $ (8,986) General and administrative expenses include employee compensation and related personnel costs, including variable performance based compensation and compensation expense for share-based awards, office and facilities costs, legal and accounting professional fees, public relations, stock administration, business development, fixed asset depreciation, amortization of Industrial Operations intangible assets, state taxes based on gross receipts and other corporate costs.
Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding Printronix’s and Deflecto’s operating expenses. 68 Table of Contents General and Administrative Expenses A summary of the main drivers of the increases (decreases) in general and administrative expenses is as follows: Years Ended December 31, 2024 vs. 2023 (In thousands) Personnel costs and board fees $ (285) Variable performance-based compensation costs 1,375 Other general and administrative costs 1,065 General and administrative costs - industrial operations (1,435) General and administrative costs - energy operations 3,163 General and administrative costs - manufacturing operations 4,158 Amortization of industrial operations intangible assets 2 Amortization of manufacturing operations intangible assets 609 Compensation expense for share-based awards 1,498 Non-recurring employee severance costs 784 Total change in general and administrative expenses $ 10,934 General and administrative expenses include employee compensation and related personnel costs, including variable performance based compensation and compensation expense for share-based awards, office and facilities costs, legal and accounting professional fees, public relations, stock administration, business development, fixed asset depreciation, amortization of Industrial Operations and Manufacturing Operations’ intangible assets, state taxes based on gross receipts and other corporate costs.
Critical Accounting Estimates Our consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America.
Refer to Note 16 to the consolidated financial statements elsewhere herein for additional information regarding the repurchase of common stock. Critical Accounting Estimates Our consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America.
For additional information, refer to the section above entitled “Cautionary Note Regarding Forward-Looking Statements.” General We are focused on acquiring and managing companies across industries – including but not limited to the industrial, energy, technology, and healthcare verticals.
For additional information, refer to the section above entitled “Cautionary Note Regarding Forward-Looking Statements.” General We are a disciplined value-oriented acquirer and operator of businesses across public and private markets and industries including, but not limited to, the industrial, energy and technology sectors.
Refer to "Intellectual Property Operations – Cost of Revenues " below for further discussion. • Litigation and licensing expenses increased $6.8 million, from $4.0 million to $10.8 million in 2023, primarily due to a net increase in litigation support and third-party technical consulting expenses associated with ongoing litigation.
Refer to “Intellectual Property Operations – Cost of Revenues” below for further discussion. 63 Table of Contents • Litigation and licensing expenses decreased $6.3 million, from $10.8 million to $4.4 million in 2024, primarily due to a net decrease in litigation support expenses associated with ongoing litigation.
The Company’s expected contribution to Benchmark to fund its portion of the Purchase Price for the Revolution Transaction is $57.5 million, which the Company anticipates will be funded from cash on hand.
The Company’s contribution to Benchmark to fund its portion of the Revolution Purchase Price and related fees for the Benchmark Transaction was $59.9 million, which was funded from cash on hand.
Other Income/Expense Equity Securities Investments Years Ended December 31, 2023 2022 $ Change % Change (In thousands, except percentage change values) Change in fair value of equity securities $ 31,423 $ (263,695) $ 295,118 (112 %) (Loss) gain on sale of equity securities (10,930) 125,318 (136,248) (109 %) Earnings on equity investment in joint venture 4,167 42,531 (38,364) (90 %) Total net realized and unrealized gain (loss) $ 24,660 $ (95,846) $ 120,506 (126 %) Our equity securities investments, including the Life Sciences Portfolio and trading securities portfolio, are recorded at fair value at each balance sheet date.
Other Income/Expense Equity Securities Investments Years Ended December 31, 2024 2023 $ Change % Change (In thousands, except percentage change values) Change in fair value of equity securities $ (31,412) $ 31,423 $ (62,835) (200 %) Gain (loss) on sale of equity securities 28,861 (10,930) 39,791 (364 %) Earnings on equity investment in joint venture — 4,167 (4,167) (100 %) Total net realized and unrealized gain $ (2,551) $ 24,660 $ (27,211) (110 %) 69 Table of Contents Our equity securities investments, including the Life Sciences Portfolio and trading securities portfolio, are recorded at fair value at each balance sheet date.
Cost of Revenues Years Ended December 31, 2023 2022 $ Change % Change (In thousands, except percentage change values) Inventor royalties $ 1,025 $ 1,212 $ (187) (15 %) Contingent legal fees 10,998 2,444 8,554 350 % Litigation and licensing expenses 10,771 3,970 6,801 171 % Amortization of patents 11,370 10,403 967 9 % Total $ 34,164 $ 18,029 $ 16,135 89 % Refer to detailed change explanations above for the year ended December 31, 2023 and 2022 regarding cost of revenues for our Intellectual Property Operations.
Cost of Revenues Years Ended December 31, 2024 2023 $ Change % Change (In thousands, except percentage change values) Inventor royalties $ 1,731 $ 1,025 $ 706 69 % Contingent legal fees 2,285 10,998 (8,713) (79 %) Litigation and licensing expenses 4,438 10,771 (6,333) (59 %) Amortization of patents 16,097 11,370 4,727 42 % Total $ 24,551 $ 34,164 $ (9,613) (28 %) Refer to detailed change explanations above for the years ended December 31, 2024 and 2023 regarding cost of revenues for our Intellectual Property Operations.
That purchase was funded with a combination of available cash and capital from Starboard, for a total of approximately $282.0 million at the time of acquisition. Through the end of 2023, we have received proceeds of $507.1 million as we monetized the Life Sciences portfolio.
Life Sciences Portfolio In June 2020 we acquired a portfolio of investments in 18 public and private life sciences companies (the “Life Sciences Portfolio”). That purchase was funded with a combination of available cash and capital from Starboard, for a total of approximately $282.0 million at the time of acquisition.
We retained an investment in the Life Sciences Portfolio consisting of public and private securities valued at $82.8 million at December 31, 2023.
Through the end of December 31, 2024, we have received proceeds of $564.1 million as we monetized the Life Sciences portfolio. We retained an investment in the Life Sciences Portfolio consisting of public and private securities valued at $25.7 million at December 31, 2024.
Income Taxes Years Ended December 31, 2023 2022 $ Change % Change (In thousands, except percentage change values) Income tax benefit $ 1,504 $ 16,211 $ (14,707) (91 %) Effective tax rate (2) % (13) % n/a 11 % Our income tax benefit for the year ended December 31, 2023 is primarily attributable to the use of tax attributes against 2023 earnings and the release of valuation allowance on the remaining federal net operating losses.
Our income tax benefit for the year ended December 31, 2023 is primarily attributable to the use of tax attributes against 2023 earnings and the release of valuation allowance on the remaining federal net operating losses.
The fluctuations in cash receipts for the periods presented primarily reflects the corresponding fluctuations in revenues recognized during the same periods, as described above, and the related timing of payments received from licensees and customers. Our reported cash used in operations for the year ended December 31, 2023 was $22.5 million, compared to $37.3 million in the prior year.
Cash receipts from Deflecto’s customers totaled $24.3 million for the post acquisition period from October 18, 2024 through December 31, 2024. The fluctuations in cash receipts for the periods presented primarily reflects the corresponding fluctuations in revenues recognized during the same periods, as described above, and the related timing of payments received from licensees and customers.
Cash Flows from Financing Activities Cash flows from financing activities included the following for the periods presented: Years Ended December 31, 2023 2022 (In thousands) Repurchase of common stock $ — $ (50,988) Paydown of Revolving Credit Facility (7,700) — Paydown of Senior Secured Notes (60,000) (120,000) Dividend on Series A Redeemable Convertible Preferred Stock (1,400) (2,799) Taxes paid related to net share settlement of share-based awards (614) (1,600) Proceeds from Rights Offering 79,111 — Proceeds from exercise of Series A warrants — 9,250 Proceeds from exercise of Series B warrants 49,000 — Proceeds from exercise of stock options 235 — Net cash provided by (used in) financing activities $ 58,632 $ (166,137) Cash inflows from financing activities for the year ended December 31, 2023 increased to $58.6 million, as compared to cash outflow of $166.1 million in the prior year, primarily due to activity related to the Rights Offering and Concurrent Private Rights Offering.
Refer to “Other Income/Expense – Equity Securities Investments ” above and Note 4 to the consolidated financial statements elsewhere herein for additional information related to Life Sciences Portfolio. 73 Table of Contents Cash Flows from Financing Activities Cash flows from financing activities included the following for the periods presented: Years Ended December 31, 2024 2023 (In thousands) Repurchase of common stock $ (20,288) $ — Paydown of Senior Secured Notes — (60,000) Contributions from noncontrolling interest 15,250 — Borrowings on the Revolving credit facility 86,010 — Paydown of Revolving Credit Facility (30,035) (7,700) Borrowings on the Term Loan 47,488 — Dividend on Series A Redeemable Convertible Preferred Stock — (1,400) Taxes paid related to net share settlement of share-based awards (1,092) (614) Proceeds from Rights Offering — 79,111 Proceeds from exercise of Series B warrants — 49,000 Proceeds from exercise of stock options 223 235 Net cash provided by financing activities $ 97,556 $ 58,632 Cash inflows from financing activities for the year ended December 31, 2024 increased to $97.6 million, as compared to cash inflows of $58.6 million in the prior year, primarily due to net cash inflows from borrowings on the Benchmark Revolving Credit Facility and Deflecto Term Loan and contributions from noncontrolling interest related to the Revolution Transaction.
Cost of Revenues Years Ended December 31, 2023 2022 $ Change % Change (In thousands, except percentage change values) Cost of revenues - industrial operations $ 18,009 $ 19,359 $ (1,350) (7 %) Refer to detailed change explanations above for the years ended December 31, 2023 and 2022 regarding cost of revenues for our Industrial Operations.
Refer to “Industrial Operations Business” above for additional information related to Printronix’s operating activities. 66 Table of Contents Cost of Revenues Years Ended December 31, 2024 2023 $ Change % Change (In thousands, except percentage change values) Cost of revenues - industrial operations $ 14,912 $ 18,009 $ (3,097) (17 %) Refer to detailed change explanations above for the years ended December 31, 2024 and 2023 regarding cost of revenues for our Industrial Operations.
Income before income taxes was $67.4 million for the year ended December 31, 2023, as compared to loss of $127.2 million in the prior year.
Refer to “Energy Operations - Revenues” and “Manufacturing Operations - Revenues” below for further discussion. Loss before income taxes was $38.1 million for the year ended December 31, 2024, as compared to income before income taxes of $67.4 million for the year ended December 31, 2023.
Industrial Operations Refer to "Industrial Operations Business" above for information related to Printronix's operating activities. Energy Operations Refer to "Energy Operations Business" above for information related to Benchmark's operating activities.
Industrial Operations Refer to “Industrial Operations Business” above for information related to Printronix’s operating activities. Energy Operations Refer to “Energy Operations Business” above for information related to Benchmark’s operating activities. 62 Table of Contents Manufacturing Operations Refer to “Manufacturing Operations Business” above for information related to Deflecto’s operating activities.
The costs associated with the forementioned obligations fluctuate period to period, based on the amount of revenues recognized each period, the terms and conditions of revenue agreements executed each period and the mix of specific patent portfolios, with varying economic terms and conditions, generating revenues each period. 42 Table of Contents Litigation and licensing expenses include patent-related litigation, enforcement and prosecution costs incurred by law firms and external patent attorneys engaged on either an hourly basis or a contingent fee basis.
The costs associated with the forementioned obligations fluctuate period to period, based on the amount of revenues recognized each period, the terms and conditions of revenue agreements executed each period and the mix of specific patent portfolios, with varying economic terms and conditions, generating revenues each period.
The decrease in Industrial Operations revenue of $4.6 million is due to lower units of printers sold. Refer to “Industrial Operations – Revenues ” below for further detailed discussion. In addition, post-acquisition revenues from Benchmark for the period from November 13, 2023 to December 31, 2023 contributed $848,000. Refer to “Energy Operations – Revenues ” below for further discussion.
The decrease in Industrial Operations revenue of $4.7 million is due to lower units of printers sold. Refer to “Industrial Operations – Revenues” below for further detailed discussion.
The net increase was comprised of the change in total revenues described above and other changes in operating expenses and other income or expense as follows: • Inventor royalties decreased $187,000, from $1.2 million to $1.0 million in 2023, primarily due to license agreement activity and related revenues generated in 2023 with no inventor royalty obligations.
The net decrease was comprised of the change in total revenues described above and other changes in operating expenses and other income or expense for the year ended December 31, 2024 as compared to the year ended December 31, 2023 as follows: • Inventor royalties increased $706,000, from $1.0 million to $1.7 million in 2024, primarily due to a higher mix of portfolios generating revenue in 2024 with inventor royalties.
The increase is primarily due to change in accounts receivable, which is related to the timing of the cash receipts related to Intellectual Property Operations Business. 48 Table of Contents Cash Flows from Investing Activities Cash flows from investing activities were comprised of the following for the periods presented: Years Ended December 31, 2023 2022 (In thousands) Acquisition, net of cash acquired (Note 3) $ (9,409) $ — Cash reinvested 9,965 — Patent acquisition (6,000) (5,000) Purchases of equity securities (13,072) (112,142) Sales of equity securities 32,106 273,934 Distributions received from equity investment in joint venture 2,777 28,404 Purchases of property and equipment (189) (732) Net cash provided by investing activities $ 16,178 $ 184,464 Cash flows from investing activities for the year ended December 31, 2023 decreased to $16.2 million, as compared to cash flow of $184.5 million in the prior year, primarily due to net cash inflows from our Life Sciences Portfolio, trading securities portfolio equity securities transactions and Acacia's acquisition of Benchmark in 2023.
Cash Flows from Investing Activities Cash flows from investing activities were comprised of the following for the periods presented: Years Ended December 31, 2024 2023 (In thousands) Acquisition, net of cash acquired (Note 3) $ (87,678) $ (9,409) Cash reinvested — 9,965 Patent acquisition $ (14,000) $ (6,000) Purchases of equity securities $ (20,472) $ (13,072) Sales of equity securities 57,854 32,106 Distributions received from equity investment in joint venture — 2,777 Net purchases of property and equipment and additions to oil and gas properties (148,667) (189) Net cash (used in) provided by investing activities $ (212,963) $ 16,178 Cash outflows from investing activities for the year ended December 31, 2024 was $213.0 million, as compared to cash inflows of $16.2 million in the prior year, primarily due to the net effect of the acquisition of oil and gas properties in the Revolution Transaction, the acquisition of Deflecto, and net cash inflows from our trading securities portfolio equity securities transactions and sale of Arix shares.
Refer to "Industrial Operations – Cost of Revenues " and "Operating Expenses" below for further discussion. • Post-acquisition cost of production from Benchmark for the period from November 13, 2023 through December 31, 2023 added operating expenses in the amount of $656,000 in 2023.
Refer to “Energy Operations – Cost of Production ” below for further discussion. • Post-acquisition cost of sales, engineering and development expenses, and sales and marketing expenses from Deflecto for the period from October 18, 2024 to December 31, 2024 added operating expenses in the amount of $18.6 million.